Stock listing

NASDAQ:RVMD Revolution Medicines, Inc. Stock

Home listing (NASDAQ) of Revolution Medicines, Inc.

Follow Revolution Medicines, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:RVMD

$182.15 USD +4.19 (+2.4%)

Close on Oct 19, 2026

Since Jul 6, 2026 -4.1% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
$177.95 – $183.87 USDOct 19, 2026
Volume
1.98M sharesOct 19, 2026
Market value
$39.04B USDAt the close on Oct 19, 2026 · price × 214.3M shares outstanding
Revolution Medicines, Inc. logo
Ticker
NASDAQ:RVMD
Asset type
Stock
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Revolution Medicines (NASDAQ:RVMD) Q2 2026 Earnings Call

    Wed, Aug 05, 2026 · 4:30 PM ET

    Watch Transcript

  • Revolution Medicines (NASDAQ:RVMD) Q1 2026 Earnings Call

    Wed, May 06, 2026 · 4:30 PM ET

    Watch Transcript

  • Revolution Medicines (NASDAQ:RVMD) Q4 2025 Earnings Call

    Wed, Feb 25, 2026 · 4:30 PM ET

    Watch Transcript

Latest news

Revolution Medicines’ RASONQUE™ (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

Oct 15, 2026

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

Oct 5, 2026

Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer

Sep 14, 2026

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

Sep 2, 2026

U.S. FDA Approves Revolution Medicines' RASONQUE (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

Aug 27, 2026

Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration

Aug 11, 2026

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Aug 5, 2026

Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026

Jul 29, 2026

Revolution Medicines New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer

Jul 23, 2026

European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

Jul 7, 2026

All Revolution Medicines, Inc. news

Decks

Revolution Medicines, Inc. on 6ix

News releases
45 in the last 12 months · 167 in all · newest Oct 15, 2026 · oldest 2020
Calls
21 calls with a replay · 21 with a transcript · latest Aug 5, 2026
Decks
16 decks · latest Aug 26, 2026

Where Revolution Medicines, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:RVMD · Home listing · This pageNASDAQUnited StatesUSD
gettex:42ZgettexGermanyEUR
LS Exchange:A2PYWGLS ExchangeGermanyEUR
Milan:1RVMDMilanItalyEUR
Tradegate:42ZTradegateGermanyEUR
BX Swiss:RVMDBX SwissSwitzerlandCHF
BOATS:RVMDBOATSUnited StatesUSD
Lang & Schwarz:A2PYWGLang & SchwarzGermanyEUR
BMV:RVMDBMVMexicoMXN
Dusseldorf:42ZDusseldorfGermanyEUR
Frankfurt:42ZFrankfurtGermanyEUR
Hamburg:42ZHamburgGermanyEUR
Munich:42ZMunichGermanyEUR
Stuttgart:42ZStuttgartGermanyEUR
BIVA:RVMDBIVAMexicoMXN
Hanover:42ZHanoverGermanyEUR
Xetra:42ZXetraGermanyEUR

Log in to ask 6ix AI your own questions about Revolution Medicines, Inc.